Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Full Show: Bloomberg Businessweek (05/26)
31:49 - Bloomberg Television takes you behind the scenes of our award-winning magazine "Bloomberg Businessweek." Hosts Carol Massar and Oliver Renick talk with the writers who break news on a weekly basis. (Source: Bloomberg)
  • Full Show: Best of Bloomberg Technology (05/26)
  • Brown Brothers' Thin Favors Asia Over Latin America
  • The Sharing Economy's Entrepreneurial Ecosystems